Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Moderate Persistent Asthma Clear all
Completed Phase 4 Interventional

Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

NCT00691873
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Xolair
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 6, 2008 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Not applicable Interventional Results available

Fenzian Asthma Multicenter Outcomes Study

NCT00784758
View directory record Official record
Conditions
Asthma
Interventions
Fenzian Device, Sham Device
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years to 80 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

NCT01312961
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
50
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

NCT02105012
View directory record Official record
Conditions
Asthma
Interventions
BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg, BD MDI 40 µg, Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
41
States / cities
Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

Effect of Medical Food on Reducing Asthma Symptoms in Asthmatic Children

NCT01087710
View directory record Official record
Conditions
Asthma
Interventions
medical food with EPA and GLA, vitamins and minerals, medical food minus EPA and GLA, antioxidant vitamins/minerals
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
6 Years to 14 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2010 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

NCT00079937
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo, Fluticasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
56
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 23, 2026, 9:24 PM EDT
Not yet recruiting Phase 1 Interventional

Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)

NCT07600190
View directory record Official record
Conditions
Asthma (Diagnosis), Persistent Asthma, Moderate Asthma Exacerbation
Interventions
Anakinra 100 Mg/0.67 Ml Inj Syringe, Saline Placebo/0.67 Ml Inj Syringe
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

NCT00044824
View directory record Official record
Conditions
Asthma
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

NCT01172808
View directory record Official record
Conditions
Asthma
Interventions
Placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Huntington Beach, California • Mission Viejo, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

Dose Finding Study for QAW039 in Asthma

NCT01437735
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Montelukast, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Scottsdale, Arizona • Encinitas, California • Huntington Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma

NCT00280683
View directory record Official record
Conditions
Asthma
Interventions
L-arginine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma

NCT02322775
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
17
States / cities
Los Angeles, California • Rolling Hills Estates, California • Clearwater, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

NCT00044811
View directory record Official record
Conditions
Asthma
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

Control of Asthma Patients Symptomatic on Inhaled Corticosteroids

NCT00330070
View directory record Official record
Conditions
Asthma
Interventions
IPL512,602 20 mg once daily, IPL512,602 Matching Placebo once daily
Drug
Lead sponsor
Inflazyme Pharmaceuticals Ltd
Industry
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2007 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

NCT04773678
View directory record Official record
Conditions
Moderate to Severe Persistent Asthma
Interventions
CBP-201, Placebo
Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Tucson, Arizona • Huntington Beach, California • Lancaster, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma

NCT01556607
View directory record Official record
Conditions
Drug Safety
Interventions
MDT-637, Placebo
Drug
Lead sponsor
MicroDose Therapeutx, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Costa Mesa, California
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma

NCT00667992
View directory record Official record
Conditions
Asthma
Interventions
Budesonide HFA, Budesonide CFC
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 23, 2026, 9:24 PM EDT
Terminated Phase 4 Interventional Results available

Moderate to Persistent Asthma in the Obese Subject

NCT01016847
View directory record Official record
Conditions
Asthma
Interventions
Montelukast, Sugar pill
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Oct 23, 2026, 9:24 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma.

NCT01939951
View directory record Official record
Conditions
Mild to Moderate Persistent Asthma
Interventions
Activation Energy Serum
Dietary Supplement
Lead sponsor
California Allergy and Asthma Medical Group, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2013 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

NCT00096616
View directory record Official record
Conditions
Asthma
Interventions
Combivent® CFC MDI, Albuterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Lakewood, California • Palmdale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Pharmacokinetics of QAW039

NCT01253603
View directory record Official record
Conditions
Persistent Asthma
Interventions
QAW039 capsules once daily for 28 days, Placebo to QAW039 capsules once daily for 28 days, Fluticasone propionate inhaler twice daily for 28 days
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Not applicable Interventional

Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma

NCT02715375
View directory record Official record
Conditions
Asthma
Interventions
CREON2000A
Device
Lead sponsor
General Innovations and Goods, Inc.
Industry
Eligibility
6 Years to 18 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Homestead, Florida • Lexington, Kentucky • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 23, 2026, 9:24 PM EDT
Completed Not applicable Interventional

Asthma In-Home Monitoring (AIM) Trial

NCT00282516
View directory record Official record
Conditions
Mild, Moderate and Severe Persistent Asthma as Defined by NHLBI-2 Guidelines
Interventions
In-home telemonitoring of pediatric patients with persistent asthma
Procedure
Lead sponsor
Tripler Army Medical Center
Federal
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Tripler AMC, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 23, 2026, 9:24 PM EDT